oral contraceptives
Commercial- Indications
- Contraception
Company intelligence / Profile preview
Prior to its acquisition by Mylan in 2015 for $750–800 million, Famy Care was a leading manufacturer of women’s healthcare products—especially hormonal contraceptives and intrauterine devices. It was the first generics company to receive WHO prequalification for hormonal contraceptives and had a significant presence in global markets. After the acquisition, its women’s health business became part of Mylan's portfolio.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Famy Care Ltd..